Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology · 2016 · 2.6K citations · Full text

Medicine, Oncology, Surgery +14

The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

Arne Warth, Thomas Muley, Michael Meister et al. · Journal of Clinical Oncology · 2012 · 703 citations

Medicine, Oncology, Pathology +17

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

Justin A. Bishop, Julie Teruya‐Feldstein, William H. Westra et al. · Modern Pathology · 2011 · 390 citations

Medicine, Molecular Biology, Oncology +12

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

K.M. Kerr, L. Bubendorf, Martin J. Edelman et al. · Annals of Oncology · 2014 · 300 citations · Full text

Medicine, Oncology, Pathology +17